

RESEARCH MONOGRAPH . COMPOUND PROFILE

Oxiracetam

A hydroxylated cyclic derivative of gamma-aminobutyric acid developed by ISF in Italy as a second-generation racetam nootropic, distinguished from piracetam by enhanced potency, positive allosteric modulation of AMPA receptors, stimulation of membrane-bound protein kinase C, and augmentation of hippocampal glutamate and acetylcholine release.

DOCUMENT	KDC-MN-1427
ISSUED	2026-05-11
REVISION	1.0
AUTHOR	Kodiac bioLabs Research
COMPOUND CLASS	2-Pyrrolidinone nootropic of the racetam family with positive allosteric modulation of AMPA-type glutamate receptors and protein kinase C activation

ABSTRACT

Oxiracetam (ISF 2522, CGP 21690E) is a synthetic nootropic of the 2-pyrrolidinone (racetam) class, first synthesized in 1974 at the Istituto di Ricerche Farmacologiche (ISF) in Milan and introduced to the Italian market in 1984 under the trade name Neuromet for the treatment of cognitive disorders associated with primary degenerative dementia and multi-infarct dementia of mild to moderate degree. The compound is the 4-hydroxy analog of piracetam, the parent racetam; the hydroxyl substitution at position 4 of the pyrrolidinone ring produces a chiral center and confers approximately 2- to 5-fold greater potency than piracetam in standard rodent learning and memory paradigms and in in vitro assays of neurotransmitter release and synaptic potentiation. Oxiracetam is supplied and marketed as the racemic mixture of (R)- and (S)-enantiomers, though recent research has identified (S)-oxiracetam as the pharmacologically active enantiomer responsible for cognitive improvement in chronic cerebral hypoperfusion models.

The mechanism of action of oxiracetam is multimodal and incompletely characterized at the molecular level, consistent with the broader racetam class. The principal identified activities include positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, producing enhanced glutamatergic neurotransmission and facilitation of long-term potentiation in hippocampal circuits; stimulation of membrane-bound protein kinase C (PKC), particularly the alpha and gamma isoforms, with consequent phosphorylation of substrates involved in memory consolidation and synaptic

plasticity; augmentation of hippocampal acetylcholine release through modulation of cholinergic interneuron excitability; and stimulation of phospholipid metabolism in neuronal membranes. Oxiracetam also increases the release of endogenous glutamate and D-aspartic acid from depolarized hippocampal slices, supporting a presynaptic facilitatory component of its mechanism. A 2020 study further demonstrated that oxiracetam attenuates amyloid-beta-induced microglial activation and reduces neuroinflammatory cytokine release (interleukin-1-beta, interleukin-6, and tumor necrosis factor alpha), adding an anti-inflammatory dimension to the pharmacological profile.

Pharmacokinetics in humans are characterized by oral bioavailability of 56 to 82 percent, peak plasma concentrations within 1 to 3 hours of dosing, and an elimination half-life of approximately 8 hours in healthy subjects. The compound is not appreciably metabolized; approximately 84 percent of an administered oral dose is recovered unchanged in urine within 24 hours, reflecting predominantly renal clearance. Brain penetration is modest, with central nervous system concentrations reaching approximately 5.3 percent of simultaneous blood levels. In patients with renal impairment, the elimination half-life extends to 10 to 68 hours, necessitating dose adjustment. The compound does not bind significantly to plasma proteins and does not undergo hepatic cytochrome P450 metabolism, resulting in a low drug-drug interaction potential.

The clinical evidence base spans multiple indications. In mild to moderate dementia of the Alzheimer type and multi-infarct dementia, multicenter randomized placebo-controlled trials conducted in Italy in the late 1980s and early 1990s demonstrated statistically significant improvements in cognitive function at 800

mg twice daily for 12 to 52 weeks, measured by the Mini Mental State Examination, memory batteries, and functional scales. A negative trial in Alzheimer's disease (Green et al., 1992) and mixed results in traumatic brain injury temper the clinical profile. More recently, a 2025 multicenter phase 3 trial of the purified (S)-enantiomer (L-oxiracetam) in 590 patients with mild to moderate traumatic brain injury reported significantly greater cognitive improvement than both racemic oxiracetam and placebo at 90 days. A 2023 phase IV trial of racemic oxiracetam in post-stroke vascular cognitive impairment in South Korea did not support efficacy in preventing cognitive decline. The compound is approved as a prescription medicine in Italy, select European countries, Argentina, and China; it is not approved by the United States Food and Drug Administration.

This monograph reviews the chemistry, stereochemistry, and synthesis of oxiracetam; the multimodal molecular pharmacology including AMPA receptor modulation, PKC activation, neurotransmitter release augmentation, and anti-inflammatory activity; the comprehensive human pharmacokinetic record; the clinical evidence base across dementia, vascular cognitive impairment, traumatic brain injury, and neuroprotection indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five nootropic alternatives against oxiracetam on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Oxiracetam.

Marketed names: Neuromet (SmithKline Beecham, later GlaxoSmithKline; Italy), Neupan (Italy), Neuractiv (Italy). The compound is marketed in China under several generic trade names for vascular and degenerative dementia indications.

Development codes: ISF 2522 (Istituto di Ricerche Farmacologiche, Milan). CGP 21690E (Ciba-Geigy). The ISF development code is the canonical identifier in the early pharmacology and clinical literature [1, 2].

Chemical Abstracts Service registry numbers: 62613-82-5 (racemic free base). The (S)-enantiomer is registered separately as CAS 89490-41-5. The compound is supplied as the racemic mixture in all currently marketed formulations; the purified (S)-enantiomer (L-oxiracetam) is in clinical development as a separate pharmaceutical entity.

International Union of Pure and Applied Chemistry name: (RS)-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide. The compound is the 4-hydroxy derivative of piracetam (2-(2-oxopyrrolidin-1-yl)acetamide), with the hydroxyl group introducing a chiral center at the 4-position of the pyrrolidinone ring.

1.2 Structural class and chemistry

Oxiracetam belongs to the racetam class of nootropic compounds, a family defined by the shared 2-pyrrolidinone (gamma-lactam) core bearing an N-acetamide substituent. The class includes piracetam (the parent compound), aniracetam, pramiracetam, phenylpiracetam, and several other analogs with varying substituent profiles [3]. Oxiracetam is distinguished from piracetam solely by the 4-hydroxyl group on the pyrrolidinone ring, a modification that increases polarity, introduces chirality, and produces enhanced biological activity in most pharmacological assays.

Molecular formula: C₆H₁₀N₂O₃.

Exact mass: 158.0691 g/mol (monoisotopic).

Molecular weight: 158.16 g/mol.

Physical properties: White crystalline powder. Freely soluble in water, soluble in methanol, sparingly soluble in ethanol and acetone, practically insoluble in diethyl ether and chloroform. Melting point approximately 165 to 168 degrees Celsius. The compound is hygroscopic and should be stored in airtight containers protected from moisture.

Stereochemistry: Oxiracetam contains one chiral center at carbon 4 of the pyrrolidinone ring and is marketed as the racemic mixture of (R)- and (S)-enantiomers. Research by Li et al. (2017) demonstrated that (S)-oxiracetam is the active enantiomer responsible for alleviating cognitive impairment induced by chronic cerebral hypoperfusion in rats, while (R)-oxiracetam was inactive [4]. The (S)-enantiomer has a higher absorption rate and a slower elimination rate than the (R)-form. Investigators acquiring research-grade oxiracetam should confirm whether the racemic or enantiopure form is required for their application and verify enantiomeric composition by chiral high-performance liquid chromatography.

1.3 Synthesis

The synthesis of oxiracetam proceeds from commercially available starting materials through several published routes. The classical approach involves the condensation of 4-hydroxy-2-pyrrolidinone with chloroacetamide or bromoacetamide under basic conditions to yield the racemic product [5]. Alternative routes employ methyl 4-chloroacetoacetate or ethyl acetoacetate as precursors, proceeding through cyclization to the 4-hydroxypyrrolidinone intermediate followed by N-alkylation with a haloacetamide. The product is purified by recrystallization from ethanol, isopropanol, or ethanol-water mixtures and characterized by nuclear magnetic resonance spectroscopy, melting point determination, and high-performance liquid chromatography. Enantioselective synthesis of (S)-oxiracetam has been achieved through asymmetric reduction or chiral resolution methods, producing material with greater than 99 percent enantiomeric excess for investigational use. Industrial synthesis typically achieves yields of 60 to 80 percent with purity greater than 99 percent by HPLC for the racemic product.

2. Abstract

Oxiracetam (ISF 2522) is a synthetic nootropic of the 2-pyrrolidinone (racetam) family, characterized by positive allosteric modulation of AMPA-type glutamate receptors, stimulation of membrane-bound protein kinase C, augmentation of hippocampal acetylcholine and glutamate release, and modulation of neuronal phospholipid metabolism [1, 6, 7, 8]. The compound was synthesized in 1974 at the Istituto di Ricerche Farmacologiche in Milan as a structural analog of piracetam bearing a 4-hydroxyl substitution on the pyrrolidinone ring, a modification that confers approximately 2- to 5-fold greater potency than the parent compound in standard learning and memory paradigms while preserving the favorable tolerability profile characteristic of the racetam class.

The principal clinical application is the treatment of cognitive impairment associated with mild to moderate primary degenerative dementia and multi-infarct (vascular) dementia, for which the compound is registered in Italy, select European jurisdictions, Argentina, and China at oral doses of 800 mg twice daily. Pivotal multicenter trials conducted by Villardita et al. (1992) in 60 patients and by Maina et al. (1989) in 307 patients demonstrated statistically significant improvements on the Mini Mental State Examination, memory batteries, attention tests, and daily functioning measures compared to placebo over 12 to 52 weeks of treatment [9, 10]. A negative trial by Green et al. (1992) in 24 Alzheimer's disease patients at Emory University failed to demonstrate cognitive improvement, suggesting that the compound may be more effective in mixed or vascular dementia than in pure Alzheimer's pathology [11].

Recent clinical development has focused on two directions. First, a 2025 multicenter phase 3 trial in China enrolled 590 patients with mild to moderate traumatic brain injury and demonstrated that (S)-oxiracetam (L-oxiracetam) at 4 g/day produced significantly greater cognitive improvement than racemic oxiracetam at 6 g/day and placebo at 90 days, as measured by the Loewenstein Occupational Therapy Cognitive Assessment [12]. Second, a 2023 phase IV trial in South Korea enrolling 500 post-stroke patients did not support the efficacy of racemic oxiracetam at 800 mg twice daily for 36 weeks in preventing cognitive decline, though limitations in patient selection and endpoint sensitivity were noted [13].

Pharmacokinetics are straightforward: oral bioavailability is 56 to 82 percent, peak plasma concentration is achieved in 1 to 3 hours, and the elimination half-life is approximately 8 hours in healthy subjects. The compound undergoes negligible hepatic metabolism, with 84 percent excreted unchanged in urine. Renal impairment substantially prolongs elimination. Brain penetration is modest at approximately 5.3 percent of plasma concentrations, with preferential distribution to the septum pellucidum and hippocampus [14, 15].

The compound is well tolerated at registered doses. Reported adverse events are mild and infrequent, comprising headache, insomnia, gastrointestinal discomfort, and nervousness. No severe adverse events, organ toxicity, or clinically significant laboratory abnormalities have been reported in clinical trials of up to 52 weeks duration at doses up to 1600 mg daily [9, 16].

This monograph documents the chemistry, stereochemistry, and synthesis of oxiracetam; the multimodal molecular pharmacology; the human pharmacokinetic profile; the clinical evidence base across dementia, vascular cognitive impairment, traumatic brain injury, and neuroprotection indications; sourcing and quality verification; reconstitution and handling; stack interactions; adverse-event signal; and a structured comparative assessment of five nootropic alternatives (piracetam, aniracetam, pramiracetam, phenylpiracetam, alpha-GPC) against oxiracetam on five competency standards.

3. Discovery and Development History

3.1 Origin

Oxiracetam was synthesized in 1974 at the Istituto di Ricerche Farmacologiche (ISF) in Milan, Italy, as part of a systematic structure-activity program exploring modifications of piracetam, the first racetam nootropic developed by Corneliu Giurgea at UCB in Belgium in 1964 [1]. The rationale was straightforward: piracetam had demonstrated cognitive enhancement in preclinical models and in early clinical studies in dementia but with modest potency, and ISF sought to identify analogs with greater activity while preserving the favorable safety margin. The 4-hydroxyl substitution was selected as a small, polar modification that could alter the electronic and hydrogen-bonding properties of the pyrrolidinone ring without fundamentally changing the pharmacophore. The resulting compound, designated ISF 2522, showed superior potency to piracetam in passive avoidance, active avoidance, and radial arm maze paradigms in rodents and was advanced to preclinical development.

3.2 Preclinical development

During the late 1970s and early 1980s, ISF and collaborating laboratories characterized the pharmacological profile of oxiracetam in a series of studies that remain the foundational preclinical literature. The compound reversed scopolamine-induced amnesia in rats and mice at intraperitoneal doses of 50 to 100 mg/kg [17]. It increased acetylcholine release from the rat hippocampus in vivo, with a 100 mg/kg dose producing a 63 percent increase in extracellular acetylcholine measured by microdialysis [18]. Contemporaneous work demonstrated that oxiracetam increased the release of endogenous glutamate and D-aspartic acid from depolarized rat hippocampal slices, indicating a presynaptic facilitatory action on excitatory neurotransmission [19]. Studies of protein kinase C activation showed that oxiracetam increased membrane-bound PKC activity in the hippocampus and cerebral cortex, with the translocation from soluble to membrane-bound fractions correlating with improved spatial learning performance in treated mice [8].

3.3 Clinical registration

Oxiracetam received its first marketing authorization in Italy in 1984 under the trade name Neuromet for the treatment of cognitive disorders associated with primary degenerative dementia and multi-infarct dementia of mild to moderate degree. The registration was based on the preclinical pharmacology package and on early clinical studies including the Itil et al. (1982) double-blind comparison with piracetam in patients with organic brain syndrome, which demonstrated superiority of oxiracetam over piracetam on several cognitive measures [2]. Subsequent registrations followed in select European countries, in Argentina, and in China during the late 1980s and 1990s. SmithKline Beecham (now GlaxoSmithKline) was the marketing authorization holder in Italy; the development code CGP 21690E reflects a parallel evaluation by Ciba-Geigy. The compound was never submitted for approval to the United States Food and Drug Administration.

3.4 Post-marketing clinical expansion

Following initial registration, the clinical research program expanded to include larger multicenter trials. The Villardita et al. (1992) study in 60 patients with Alzheimer-type and multi-infarct dementia confirmed sustained cognitive benefit over 12 months [9]. The Maina et al. (1989) multicenter trial in 307 patients is the largest completed study and provided the strongest support for the registered dementia indication [10]. The Green et al. (1992) trial at Emory University, however, reported negative results in a 24-patient Alzheimer's cohort, introducing heterogeneity into the clinical evidence [11].

3.5 Contemporary development: the (S)-enantiomer

Beginning in the mid-2010s, Chinese pharmaceutical research groups pursued the development of the purified (S)-enantiomer (L-oxiracetam) as a potentially superior alternative to the racemic mixture. Li et al. (2017) demonstrated that (S)-oxiracetam was the active ingredient in the racemate responsible for cognitive improvement in a rat model of chronic cerebral hypoperfusion [4]. This finding provided the pharmacological rationale for clinical development of the single enantiomer. A phase 1 study in Chinese healthy volunteers established the safety and pharmacokinetic profile of oral (S)-oxiracetam [20]. The LOCATE trial, a multicenter, randomized, double-blind phase 3 study enrolling 590 patients with mild to moderate traumatic brain injury across 51 hospitals in China, reported in 2025 that L-oxiracetam at 4

g/day produced significantly greater cognitive improvement than racemic oxiracetam at 6 g/day and placebo, establishing the single enantiomer as a clinical candidate with potentially superior efficacy [12].

4. Molecular Pharmacology

Oxiracetam is a multimodal neuroactive compound. Its principal molecular activities, characterized in heterologous expression systems, brain slice preparations, and in vivo microdialysis and behavioral models, include positive allosteric modulation of AMPA-type glutamate receptors, stimulation of membrane-bound protein kinase C, augmentation of acetylcholine and glutamate release from hippocampal neurons, modulation of neuronal phospholipid metabolism, and attenuation of neuroinflammatory microglial activation. These activities collectively support the observed procognitive effects across learning, memory, and attention domains.

4.1 AMPA receptor positive allosteric modulation

The alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor is a tetrameric ionotropic glutamate receptor composed of GluA1 through GluA4 subunits, expressed at excitatory synapses throughout the cortex and hippocampus, where it mediates the fast component of glutamatergic neurotransmission and plays a central role in long-term potentiation (LTP), the cellular correlate of learning and memory [6].

Oxiracetam acts as a positive allosteric modulator (PAM) of the AMPA receptor, binding at a site distinct from the glutamate binding pocket and enhancing receptor function without directly activating it in the absence of agonist. Crystal structure analyses indicate that the hydroxyl group of oxiracetam forms a critical hydrogen bond with residues on the GluA2 subunit at the allosteric modulatory site [6]. The functional consequence is slowed desensitization of GluA1 and GluA2 subunits, with no significant effect on receptor inactivation kinetics, and promotion of recovery from desensitization specifically in GluA2-containing receptors [21]. The net effect is prolonged AMPA receptor-mediated excitatory postsynaptic currents at glutamatergic synapses, resulting in enhanced calcium influx, facilitated LTP induction, and improved synaptic efficiency in hippocampal and cortical circuits.

The AMPA PAM activity distinguishes oxiracetam from piracetam, which shows weaker and less well-characterized interaction with ionotropic glutamate receptors, and places it in the same mechanistic category as the ampakine class of cogni-

tive enhancers (CX516, CX717, and others), though with substantially lower potency than purpose-designed ampakines.

4.2 Protein kinase C activation

Protein kinase C (PKC) is a family of serine/threonine kinases critically involved in memory consolidation, synaptic plasticity, and neurotransmitter release. Oxiracetam stimulates the translocation of PKC from the soluble (cytosolic) to the membrane-bound (particulate) fraction in the hippocampus and cerebral cortex, an event that represents enzyme activation [8]. The effect is selective for the alpha and gamma isoforms of PKC, both of which are enriched in hippocampal pyramidal neurons and are required for the induction and maintenance of LTP.

Fordyce et al. (1995) demonstrated that repeated daily administration of oxiracetam to mice produced a significant increase in membrane-bound PKC activity in the hippocampus that correlated with improved spatial learning performance in the Morris water maze [8]. The temporal profile of PKC activation showed an early increase in particulate (membrane-bound) activity accompanied by a decrease in soluble activity, followed hours later by downregulation. This pattern is consistent with a physiological signaling cascade in which membrane translocation activates the enzyme, and subsequent downregulation prevents excessive kinase activity.

The downstream consequences of PKC activation include phosphorylation of AMPA receptor subunits (promoting their insertion into the postsynaptic membrane), phosphorylation of the myristoylated alanine-rich C kinase substrate (MARCKS) protein (involved in actin dynamics and spine remodeling), and modulation of presynaptic vesicle release machinery. PKC activation therefore represents a convergent mechanism that reinforces the AMPA receptor modulation at the synaptic level.

4.3 Augmentation of neurotransmitter release

Oxiracetam increases the release of multiple neurotransmitters from hippocampal neurons, supporting a presynaptic component of its procognitive activity.

Acetylcholine: Giovannini et al. (1993) demonstrated that oxiracetam at 100 mg/kg intraperitoneally produced a 63 percent increase in acetylcholine release from the rat hippocampus measured by in vivo microdialysis [18]. The magnitude and duration of the acetylcholine increase exceeded that produced by equimolar

doses of piracetam. Repeated daily dosing produced a 31 percent increase in acetylcholine utilization relative to controls, indicating sustained cholinergic facilitation rather than acute release followed by depletion [22]. The cholinergic augmentation is believed to involve indirect modulation of cholinergic interneuron excitability through glutamatergic facilitation rather than direct action at cholinergic receptors or on the acetylcholine synthetic enzyme choline acetyltransferase.

Glutamate and D-aspartic acid: Bhargava et al. (1990) demonstrated that oxiracetam increased the release of endogenous glutamate and D-aspartic acid from depolarized rat hippocampal slices, indicating a presynaptic facilitatory action on excitatory amino acid neurotransmission [19]. The effect was concentration-dependent and was observed under conditions of potassium-evoked depolarization, consistent with augmentation of vesicular release rather than reversal of reuptake transporters. Oxiracetam also prevented the hippocampal cholinergic hypofunction induced by the NMDA receptor blocker AP7, indicating interaction between the glutamatergic and cholinergic facilitatory mechanisms [23].

4.4 Phospholipid metabolism

Oxiracetam stimulates the rate of phospholipid metabolism in neuronal membranes, with the effect exceeding that of control conditions and operating more on the turnover of phospholipids than on their rate of synthesis from injected precursors [24]. The enhanced phospholipid turnover is hypothesized to contribute to membrane fluidity, receptor trafficking, and synaptic vesicle cycling, all of which are components of efficient neurotransmission. This mechanism is shared with piracetam and is considered a class effect of the racetam nootropics, though oxiracetam produces the effect at lower concentrations than piracetam.

4.5 Anti-inflammatory and neuroprotective activity

Zhang et al. (2020) demonstrated that oxiracetam attenuates amyloid-beta-induced microglial activation in BV2 microglial cells and reduces the release of proinflammatory cytokines including interleukin-1-beta, interleukin-6, and tumor necrosis factor alpha [25]. The compound rescued the reduction in HT22 neuronal cell viability induced by conditioned medium from amyloid-beta-activated microglia, indicating neuroprotection against indirect (inflammation-mediated) neurotoxicity rather than direct amyloid-beta toxicity. This anti-inflammatory mechanism adds a

dimension to the pharmacological profile that is relevant to neurodegenerative conditions characterized by chronic neuroinflammation, including Alzheimer's disease and vascular dementia.

Separate preclinical work has demonstrated that oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis and autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway [26], suggesting neuroprotective activity that extends beyond acute symptomatic cognitive enhancement.

4.6 Composite pharmacology

The composite pharmacology of oxiracetam at the registered 800 mg twice-daily oral dose produces plasma concentrations of approximately 19 to 31 micrograms per milliliter at peak (120 to 210 micromolar). Brain concentrations reach approximately 5.3 percent of plasma levels, corresponding to approximately 6 to 11 micromolar in central nervous system tissue. At these concentrations, AMPA receptor positive allosteric modulation is achievable (the racetam class operates in the low-to-mid micromolar range at the AMPA receptor), PKC translocation is activated, and neurotransmitter release augmentation is supported. The clinical effect is therefore plausibly a composite of enhanced glutamatergic transmission (AMPA PAM), improved cholinergic function (acetylcholine release augmentation), enhanced synaptic plasticity (PKC activation), and maintained membrane integrity (phospholipid metabolism), with an additional anti-inflammatory component in neurodegenerative contexts.

5. Pharmacokinetics

5.1 Absorption

Oxiracetam is well absorbed from the gastrointestinal tract after oral administration. Bioavailability is 56 to 82 percent across studies, with variability attributable to differences in formulation, fasting state, and study population [14, 15]. Time to peak plasma concentration after a single 800 mg or 2000 mg oral dose is 1 to 3 hours. Maximum plasma concentration after a single 800 mg oral dose is approximately 19 micrograms per milliliter (120 micromolar); after a 2000 mg dose, approximately 31 micrograms per milliliter (196 micromolar) [14].

5.2 Distribution

Oxiracetam has a modest volume of distribution consistent with distribution primarily to total body water compartments. Plasma protein binding is low (less than 10 percent), leaving the majority of the circulating drug in the free (unbound) fraction. The compound crosses the blood-brain barrier, though penetration is limited: brain concentrations reach approximately 5.3 percent of simultaneous blood levels one hour after a single 2000 mg intravenous dose [14]. Distribution within the brain is not uniform; the highest concentrations are found in the septum pellucidum, followed by the hippocampus, consistent with preferential distribution to structures involved in learning and memory [14].

5.3 Metabolism

Oxiracetam undergoes negligible hepatic metabolism. The compound does not serve as a substrate, inhibitor, or inducer of the major cytochrome P450 isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4). The major metabolites identified in humans include beta-hydroxy-2-pyrrolidinone, N-aminoacetyl-GABOB (gamma-amino-beta-hydroxybutyric acid), GABOB, and glycine, following a degradation pathway parallel to that of piracetam [14]. These metabolites are present in trace quantities and are pharmacologically inactive. The absence of hepatic metabolism is the principal basis for the low drug-drug interaction potential of oxiracetam and distinguishes it from compounds with CYP-mediated clearance.

5.4 Elimination

Renal excretion is the principal elimination pathway. Approximately 84 percent of an administered oral dose is recovered unchanged in urine within 24 hours [15]. The elimination half-life in healthy subjects is approximately 8 hours after oral dosing. In elderly patients (ages 69 to 96), Perucca et al. (1987) reported a half-life of 3 to 6 hours after a single 800 mg oral dose, with 84 percent urinary recovery of unchanged drug, and noted that clearance is lower in the elderly as a result of the physiological decrease in renal function [15]. In patients with renal impairment, the elimination half-life extends substantially, ranging from 10 to 68 hours depending on the degree of impairment [27]. Dose adjustment is required in moderate to severe renal insufficiency.

5.5 Routes of administration

Two principal routes are used clinically and in research: oral (800 mg twice daily, registered dementia indication; 1200 to 2400 mg daily in divided doses in some clinical protocols) and intravenous (used in the phase 3 L-oxiracetam trial at 4 g/day and in pharmacokinetic characterization studies). The oral route is the standard route for all registered indications. Intramuscular administration has been used in select research protocols but is not a registered route.

5.6 Special populations

Elderly: Pharmacokinetics in the elderly show reduced renal clearance consistent with age-related decline in glomerular filtration rate. No accumulation was observed during 7 days of twice-daily 800 mg dosing in elderly women [15]. Dose adjustment based on renal function rather than age alone is appropriate.

Renal impairment: The compound is substantially cleared by the kidneys, and renal impairment produces proportional increases in exposure and half-life. Dose reduction to 800 mg once daily or every other day is recommended in moderate renal impairment; use in severe renal impairment requires careful monitoring [27].

Pediatric: Limited pharmacokinetic data are available in pediatric populations. The compound is not registered for pediatric use.

Pregnancy and lactation: Reproductive toxicology data are limited. The compound is not recommended during pregnancy or lactation.

6. Preclinical Pharmacology

6.1 Anti-amnesic activity

Oxiracetam reverses amnesia induced by scopolamine (a muscarinic antagonist that models cholinergic deficits) in rats and mice across multiple learning paradigms including passive avoidance, active avoidance, and radial arm maze [17]. The effective dose range is 30 to 100 mg/kg intraperitoneally or 100 to 300 mg/kg orally in rodents. The anti-amnesic potency is approximately 2- to 5-fold greater than piracetam and similar to aniracetam in comparable paradigms [3].

6.2 Spatial learning enhancement

Fordyce et al. (1995) demonstrated that chronic oxiracetam treatment improved spatial learning in the Morris water maze in mice, with the improvement correlating with increased membrane-bound PKC activity in the hippocampus [8]. The effect was observed in both young and aged animals, supporting relevance to both developmental learning and age-related cognitive decline.

6.3 Electrophysiology

Oxiracetam enhances field potentials in rat hippocampal slices, consistent with facilitation of synaptic transmission [28]. The (S)-enantiomer can induce long-term potentiation in hippocampal slices, while the (R)-enantiomer does not produce this effect, supporting the enantioselectivity of the procognitive mechanism [4].

6.4 Cerebral hypoperfusion model

Li et al. (2017) demonstrated that (S)-oxiracetam alleviated impairments of spatial learning and memory in a rat model of chronic cerebral hypoperfusion (bilateral common carotid artery occlusion) by ameliorating neuron damage and white matter lesions, increasing cerebral blood flow, and inhibiting astrocyte activation [4]. The (R)-enantiomer was inactive in this model. The (S)-enantiomer also regulated ATP metabolism, glutamine-glutamate cycling, and antioxidant systems in the cortex of hypoperfused rats.

6.5 Neuroprotection in Alzheimer's disease models

Zhang et al. (2020) demonstrated that oxiracetam reduced amyloid-beta-42-induced microglial activation, attenuated proinflammatory cytokine release, and rescued neuronal viability in an in vitro model of Alzheimer's disease neuroinflammation [25]. Separate work demonstrated regulation of apoptosis and autophagy pathways through Akt/mTOR signaling in vascular dementia models [26].

7. Clinical Evidence Base

7.1 Dementia of Alzheimer type and multi-infarct dementia

The principal clinical evidence for oxiracetam in dementia derives from Italian multicenter trials conducted in the late 1980s and early 1990s.

Maina et al. (1989): A multicenter, double-blind, placebo-controlled trial enrolled 307 patients with primary degenerative dementia or multi-infarct dementia of mild to moderate severity. Patients were treated with oxiracetam 800 mg twice daily or placebo for 12 weeks. The oxiracetam group demonstrated statistically significant improvements in cognitive function as measured by the Alzheimer's Deficit Scale and the Gottfries-Brane-Steen scale compared to placebo [10].

Villardita et al. (1992): A double-blind, placebo-controlled study in 60 outpatients with Alzheimer-type and multi-infarct dementia treated with oxiracetam 800 mg twice daily for 90 days demonstrated significant improvements on the Mini Mental State Examination, Auditory Continuous Performance Test, Rey's 15 Words Test, Block Tapping Test, and Mattis Word Fluency [9]. Follow-up at one year (29 of 30 oxiracetam-treated patients) confirmed sustained benefit with no severe adverse events.

Preda et al. (1988): A clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia demonstrated improvements in attentional activities and complex neuropsychological functions at 1600 mg/day [29].

Dysken et al. (1989): Long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia confirmed neuropsychological improvement compared to a control group over extended treatment [30].

Green et al. (1992) (Negative trial): A double-blind, placebo-controlled study at Emory University enrolled 24 patients with probable Alzheimer's disease. A broad battery of neuropsychological tests failed to reveal any improvement in the treated group [11]. The authors concluded that oxiracetam was ineffective in reducing cog-

nitive impairment due to Alzheimer's disease. This negative finding contrasts with the positive Italian trials and may reflect differences in patient selection (pure Alzheimer's disease versus mixed dementia), disease severity, or sample size.

7.2 Vascular cognitive impairment

Lim et al. (2023): A multicenter, randomized, double-blinded, placebo-controlled phase IV trial in South Korea enrolled 500 patients who complained of cognitive decline 3 months after stroke and had a high risk of cognitive decline. Patients received oxiracetam 800 mg twice daily or placebo for 36 weeks [13]. Co-primary endpoints were changes in the Mini Mental State Examination and Clinical Dementia Rating-Sum of Boxes. The trial did not support the efficacy of oxiracetam in preventing cognitive decline among high-risk post-stroke patients. Following completion, the Korea Ministry of Food and Drug Safety issued a drug safety communication in January 2023 recommending the suspension of oxiracetam prescriptions for the post-stroke indication.

7.3 Traumatic brain injury

LOCATE trial (2025): A multicenter, randomized, double-blind phase 3 trial across 51 hospitals in China enrolled 590 patients aged 18 to 75 years with mild to moderate traumatic brain injury [12]. Patients were randomized in a 2:2:1 ratio to L-oxiracetam 4 g/day, racemic oxiracetam 6 g/day, or placebo. The primary outcome was change in the Loewenstein Occupational Therapy Cognitive Assessment (LOTCA) score from baseline to 90 days. The least squares mean change was 20.45 in the L-oxiracetam group, 15.90 in the racemic oxiracetam group, and 11.47 in the placebo group. L-oxiracetam was significantly superior to placebo, and the numerical superiority over racemic oxiracetam was consistent with the hypothesis that the (S)-enantiomer is the active species. No significant safety concerns were reported.

Earlier TBI studies: A prior study of racemic oxiracetam in patients with mild to moderate traumatic brain injury found the compound ineffective for enhancing memory and cognitive function, consistent with the interpretation that racemic oxiracetam delivers a suboptimal dose of the active enantiomer for this indication.

7.4 Organic brain syndrome

Itil et al. (1982) conducted an early double-blind controlled comparison of oxiracetam and piracetam in patients with organic brain syndrome, demonstrating superiority of oxiracetam on several cognitive measures [2]. This study was one of the first clinical demonstrations of oxiracetam activity and contributed to the regulatory package supporting Italian marketing authorization.

7.5 Post-stroke cognitive decline prevention

The 2025 South Korean multicenter trial by Lim et al. investigated whether oxiracetam combined with physical activity could prevent cognitive decline after stroke [31]. The trial design incorporated wrist actigraphy to measure physical activity and resting-state functional MRI to assess neural network connectivity. Results from the combination analysis are pending full publication.

8. Sourcing and Quality Verification

Pharmaceutical-grade oxiracetam is available in jurisdictions where the compound is registered (Italy, select European countries, Argentina, China) as Neuromet, Neupan, or Neuractiv branded formulations and as generic equivalents, typically supplied as 400 mg or 800 mg oral tablets or capsules.

Research-grade oxiracetam is supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Cayman Chemical, Santa Cruz Biotechnology, MedChemExpress, TCI Chemicals, and others) at greater than 98 percent purity by HPLC. Supply is in gram to kilogram quantities as the racemic free base. Pricing is moderate, in the range of \$30 to \$150 per 10 grams at research-grade purity at the time of monograph preparation.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (159.0769 for the protonated molecular ion $[M+H]^+$)
- Chiral HPLC or polarimetry to determine enantiomeric composition if the application requires knowledge of (R)/(S) ratio
- Karl Fischer or loss-on-drying analysis for residual water content (the compound is hygroscopic)
- Melting point determination (165 to 168 degrees Celsius for the racemic free base)
- Residual solvent analysis if the synthetic route involves organic solvents

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade oxiracetam market is well established; lot-to-lot variability in enantiomeric composition of the racemic product is minimal, but hygroscopic degradation can affect potency if storage conditions are not maintained.

9. Reconstitution and Handling

Oxiracetam is freely soluble in water at room temperature (greater than 100 mg/mL). For research applications, the compound is supplied as a white crystalline powder and is reconstituted as needed. Stock solutions are typically prepared at 50 to 200 mg/mL in water, normal saline, or phosphate-buffered saline for in vivo and in vitro work. Dimethyl sulfoxide is not required given the high aqueous solubility but can be used for concentrated stock preparation if needed.

Storage of the solid material should be in airtight containers at room temperature (15 to 25 degrees Celsius) or refrigerated (2 to 8 degrees Celsius), protected from moisture owing to the hygroscopic nature of the compound. Desiccant packs should be included in storage containers. The solid is stable for at least 24 months under appropriate storage conditions.

Aqueous stock solutions should be prepared fresh or stored at 2 to 8 degrees Celsius and used within 7 to 14 days. Aliquoting for single-use is recommended to minimize repeated freeze-thaw cycles, though the compound shows reasonable stability through at least 3 freeze-thaw cycles without measurable loss of potency.

For clinical-research formulations, the compound is supplied as oral tablets or capsules (400 mg, 800 mg) in the marketed presentations. Intravenous formulations for clinical research are prepared in normal saline at concentrations appropriate to the dosing protocol.

10. Stack Interactions and Combinations

Oxiracetam has a low drug-drug interaction potential owing to its negligible hepatic metabolism and low plasma protein binding. Investigators conducting research with oxiracetam, especially in combination protocols, should consider:

Cholinergic agents: Concurrent acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) produce additive cholinergic facilitation. The combination is pharmacologically rational for dementia applications, as oxiracetam increases acetylcholine release while the inhibitors prevent its degradation. Additive parasympathomimetic adverse effects (nausea, diarrhea, bradycardia) should be monitored.

Choline sources: Alpha-GPC, CDP-choline (citicoline), and choline bitartrate are commonly combined with racetams in nootropic protocols to provide substrate for increased acetylcholine synthesis driven by the racetam-induced cholinergic facilitation. The combination is well tolerated and may mitigate the headache sometimes reported with racetam use alone, which is attributed to increased acetylcholine demand exceeding available choline substrate [32].

Other racetams: Concurrent use with piracetam, aniracetam, or pramiracetam produces overlapping but not identical mechanisms of action. The combination has not been formally studied in clinical trials but is used in nootropic research protocols. Additive glutamatergic facilitation is theoretically possible and should be monitored for signs of excitotoxicity at high combined doses.

Stimulants: Oxiracetam has mild stimulatory properties. Concurrent use with caffeine, modafinil, or amphetamine-class stimulants may produce additive effects on arousal, wakefulness, and potentially on anxiety and insomnia. No pharmacokinetic interaction is expected.

Renal-cleared compounds: Since oxiracetam is predominantly cleared renally, concurrent use with other compounds that depend on renal clearance or that alter renal function (aminoglycosides, lithium, high-dose nonsteroidal anti-inflamma-

tory drugs) could theoretically alter oxiracetam exposure. No formal interaction studies have been reported for these combinations.

Anticoagulants and antiplatelet agents: No pharmacokinetic or pharmacodynamic interaction has been reported. The combination is used clinically in post-stroke patients receiving standard anticoagulation or antiplatelet therapy.

Thyroid hormones: Concurrent thyroid hormone supplementation has been noted anecdotally to increase restlessness or irritability when combined with oxiracetam. No formal pharmacological basis has been established for this interaction.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events at registered doses (800 mg twice daily) are mild and infrequent:

- Headache (the most commonly reported adverse event, often attributed to increased acetylcholine demand; typically responsive to choline supplementation)
- Insomnia or sleep disturbance (particularly when doses are taken late in the day, consistent with the mild stimulatory properties)
- Nausea or gastrointestinal discomfort (mild, typically transient, more common at initiation of therapy)
- Nervousness or restlessness (mild, dose-dependent)
- Dizziness (infrequent)

These adverse-event rates are similar to or lower than those reported for piracetam and are consistent across the registered dementia indications. In the Villardita et al. (1992) 12-month study, no severe adverse events were observed and no changes in routine laboratory examinations occurred during the entire study period [9].

11.2 Long-term safety

Multiple studies have evaluated the safety of chronic oxiracetam administration at doses up to 1600 mg daily for up to 52 weeks. No organ toxicity, clinically significant laboratory abnormalities, hematological changes, or electrocardiographic changes have been reported [9, 16]. The safety margin is considered wide; preclinical toxicology studies in dogs comparing racemic oxiracetam and (S)-oxiracetam did not identify dose-limiting toxicities at multiples of the human therapeutic dose [33].

11.3 Renal considerations

The predominantly renal clearance of oxiracetam means that patients with renal impairment are at risk of drug accumulation and potential adverse effects from elevated plasma concentrations. Half-life extension to 10 to 68 hours in renal impairment necessitates dose adjustment. Monitoring of renal function is recommended during chronic therapy.

11.4 Contraindications

Known hypersensitivity to oxiracetam or other racetam compounds. Severe renal impairment (creatinine clearance less than 20 mL/min) without dose adjustment. Pregnancy and lactation (insufficient safety data).

11.5 Pregnancy and lactation

Reproductive toxicology data in humans are limited. Animal studies have not demonstrated teratogenicity at multiples of the human dose. The compound is not recommended during pregnancy or lactation owing to the absence of adequate human safety data.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five nootropic alternatives against oxiracetam, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile (clinical or in vitro), and overall validation. The five candidates were selected as the principal nootropic agents sharing structural, mechanistic, or clinical positioning with oxiracetam, with priority on those that have produced material clinical evidence.

12.1 Piracetam

Mechanism: The parent racetam nootropic. Positive allosteric modulation of AMPA receptors (weaker than oxiracetam), modulation of neuronal membrane fluidity, and enhancement of neurotransmitter function. The compound lacks the 4-hydroxyl group that confers chirality and enhanced potency on oxiracetam.

Development trajectory: Piracetam was developed by Corneliu Giurgea at UCB (Belgium) in 1964 and is the founding member of the racetam class. It is registered in numerous jurisdictions worldwide (though not in the United States) for cognitive impairment, myoclonus, and vertigo. Clinical evidence spans decades, with the largest literature of any racetam nootropic [3].

Novelty: Low. The compound is the historical reference nootropic and the most extensively studied member of its class.

Effect size: Modest. Meta-analyses of piracetam in cognitive impairment demonstrate small but statistically significant effects on cognitive composite measures. Effect sizes are generally smaller than those reported for oxiracetam in head-to-head comparisons and in comparable dementia populations. Itil et al. (1982) reported superiority of oxiracetam over piracetam in patients with organic brain syndrome [2].

Promising potential: Low. Development is mature and no new indications are in active clinical investigation. The compound persists as a reference nootropic and as a widely available over-the-counter or prescription agent in many jurisdictions.

Side-effect profile: Excellent. Piracetam is one of the best-tolerated nootropic compounds, with an adverse-event profile comparable to placebo in most clinical trials. The safety margin is wide.

Overall validation: High. The compound has the largest clinical evidence base and the longest safety record of any racetam nootropic.

Comparison to oxiracetam: Oxiracetam is more potent than piracetam in pre-clinical assays (2- to 5-fold) and in the Itil et al. (1982) clinical comparison. Both compounds share the AMPA PAM and phospholipid metabolism mechanisms. Piracetam has the advantage of a substantially larger clinical literature and broader regulatory approval. Oxiracetam has the advantage of enhanced potency and the PKC activation mechanism not shared with piracetam.

12.2 Aniracetam

Mechanism: Positive allosteric modulation of AMPA receptors (more potent than piracetam or oxiracetam at the receptor level), with additional anxiolytic activity mediated through modulation of dopaminergic and serotonergic neurotransmission. The compound is lipophilic (unlike the hydrophilic oxiracetam and piracetam) and readily crosses the blood-brain barrier [34].

Development trajectory: Developed by Hoffmann-La Roche in the 1970s and registered in Japan and several European countries for cognitive impairment. Clinical evidence includes trials in dementia and post-stroke cognitive impairment. The compound is widely available as a research-grade material and as a dietary supplement in some jurisdictions.

Novelty: Low to moderate. The anxiolytic component distinguishes aniracetam from other racetams.

Effect size: Moderate in preclinical models; clinical effect sizes in dementia are comparable to piracetam and oxiracetam. The anxiolytic effect is a clinically meaningful differentiation not shared by oxiracetam.

Promising potential: Low to moderate. Development is mature; no new large-scale clinical programs are underway.

Side-effect profile: Good. Adverse events are mild and infrequent, similar to other racetams. The lipophilicity and shorter half-life (1 to 2.5 hours) require more frequent dosing.

Overall validation: Moderate. Clinical evidence is less extensive than piracetam but includes controlled trials in dementia.

Comparison to oxiracetam: Aniracetam is more potent at the AMPA receptor and has the additional anxiolytic component. Oxiracetam has the advantages of longer half-life (8 hours versus 1 to 2.5 hours for aniracetam), water solubility, mild stimulatory properties (versus the calming effect of aniracetam), and the PKC activation mechanism. The two compounds are complementary rather than competitive and are sometimes used in combination in nootropic protocols.

12.3 Pramiracetam

Mechanism: High-affinity choline uptake enhancer, increasing the substrate availability for acetylcholine synthesis. The AMPA receptor modulation is less well characterized than for oxiracetam or aniracetam. The compound is the most potent racetam on a milligram-per-kilogram basis in rodent learning paradigms [35].

Development trajectory: Developed by Parke-Davis in the 1970s and registered in select European countries for cognitive impairment. A clinical trial in traumatic brain injury showed cognitive improvement. The compound is available as a research-grade material and in some jurisdictions as a prescription medicine.

Novelty: Low. The choline uptake enhancement mechanism is the principal distinguishing feature.

Effect size: Moderate to high in preclinical models, particularly in memory consolidation paradigms. Clinical effect sizes are less well characterized than for oxiracetam due to a smaller clinical trial literature.

Promising potential: Low to moderate. No active large-scale development programs.

Side-effect profile: Good. Adverse events are mild. The compound has a bitter taste that limits oral palatability in some formulations.

Overall validation: Moderate. Clinical evidence is less extensive than for piracetam or oxiracetam.

Comparison to oxiracetam: Pramiracetam is more potent by weight and has a more direct cholinergic mechanism (choline uptake). Oxiracetam has the advantages of a larger clinical evidence base, well-characterized AMPA PAM activity, PKC activation, and a recent large phase 3 trial of the (S)-enantiomer. The two compounds operate through partially distinct mechanisms and may be complementary.

12.4 Phenylpiracetam (Fonturacetam)

Mechanism: AMPA receptor positive allosteric modulation with additional dopaminergic and noradrenergic activity, producing pronounced psychostimulant and physical performance-enhancing effects. The phenyl group confers blood-brain barrier penetration superior to piracetam and oxiracetam [36].

Development trajectory: Developed at the Russian Academy of Sciences in the 1980s, originally as Phenotropil. Registered in Russia for cognitive impairment and asthenia. Banned by the World Anti-Doping Agency (WADA) as a performance-enhancing substance in competitive sport.

Novelty: Moderate. The stimulant component and the physical performance enhancement are unique among racetams.

Effect size: Moderate in cognitive paradigms; the stimulant effect is the most clinically noticeable component. Clinical evidence in dementia is limited and principally from Russian-language literature.

Promising potential: Low outside Russia. Limited international clinical development. Research-grade material is available from chemical suppliers.

Side-effect profile: Moderate. The stimulant activity produces insomnia, irritability, and anxiety more frequently than other racetams. The side-effect profile is less favorable than that of oxiracetam.

Overall validation: Low to moderate. Clinical evidence in internationally peer-reviewed literature is limited.

Comparison to oxiracetam: Phenylpiracetam is more stimulating and produces more pronounced acute cognitive and physical performance effects. Oxiracetam has the advantages of a more favorable side-effect profile, a larger international

clinical evidence base, and a more specific nootropic (as opposed to stimulant) mechanism. Phenylpiracetam is better suited to acute performance demands; oxiracetam to chronic cognitive support.

12.5 Alpha-GPC (L-alpha-glycerylphosphorylcholine)

Mechanism: Cholinergic precursor that crosses the blood-brain barrier and is metabolized to choline and glycerophosphate, providing substrate for acetylcholine synthesis and phospholipid incorporation. The mechanism is distinct from the racetam class; alpha-GPC operates as a nutrient precursor rather than as a receptor modulator [37].

Development trajectory: Alpha-GPC is registered in several European countries (including Italy) for cognitive impairment and dementia. Clinical trials in Alzheimer's disease and vascular dementia have demonstrated cognitive improvement at 400 mg three times daily. The compound is widely available as a dietary supplement.

Novelty: Low. The cholinergic precursor mechanism is straightforward and well characterized.

Effect size: Moderate. Clinical trials demonstrate cognitive improvement in dementia, with effect sizes broadly comparable to those reported for racetam nootropics.

Promising potential: Moderate. The compound is widely used and widely available. No large new clinical programs are underway, but ongoing use in clinical practice and in nootropic combinations maintains relevance.

Side-effect profile: Excellent. Adverse events are rare and mild (gastrointestinal discomfort, headache). The compound is one of the best-tolerated nootropic agents.

Overall validation: Moderate to high. Clinical evidence in dementia is substantial.

Comparison to oxiracetam: Alpha-GPC and oxiracetam operate through complementary mechanisms: alpha-GPC provides cholinergic substrate, while oxiracetam enhances cholinergic release and glutamatergic transmission. The two compounds

are frequently used in combination in nootropic protocols. Oxiracetam has the advantage of multimodal receptor-level activity (AMPA PAM, PKC activation); alpha-GPC has the advantage of simplicity, tolerability, and direct cholinergic support.

12.6 Comparator summary

The five compounds occupy distinct positions in the nootropic pharmacology space. **Piracetam** is the historical reference with the largest safety and efficacy database but the lowest potency. **Aniracetam** is the most potent AMPA PAM in the racetam class with a unique anxiolytic component but a short half-life. **Pramiracetam** is the most potent racetam by weight with a direct cholinergic uptake mechanism but a limited clinical literature. **Phenylpiracetam** is the most stimulating racetam with physical performance-enhancing properties but a less favorable side-effect profile and limited international evidence. **Alpha-GPC** is a cholinergic precursor with complementary mechanism and excellent tolerability but no receptor-level neuromodulatory activity.

Oxiracetam occupies a balanced position in this comparator landscape: it is more potent than piracetam, longer-acting than aniracetam, better characterized clinically than pramiracetam, better tolerated than phenylpiracetam, and mechanistically more complex than alpha-GPC. Its unique combination of AMPA receptor positive allosteric modulation, PKC activation, neurotransmitter release augmentation, and anti-inflammatory activity produces a pharmacological profile that is broader than any single comparator. The recent positive phase 3 trial of the purified (S)-enantiomer in traumatic brain injury (2025) represents the most current large-scale clinical validation of the oxiracetam pharmacophore and positions the compound for potential expanded clinical development. The principal weakness relative to the comparators is the negative Alzheimer's disease trial (Green et al., 1992) and the negative post-stroke vascular cognitive impairment trial (Lim et al., 2023), which introduce uncertainty about the breadth of clinical applicability.

Investigators considering oxiracetam for nootropic research should expect modest to moderate cognitive effect sizes consistent with the racetam class, should consider the renal clearance profile as a determinant of dosing in impaired populations, and should evaluate the comparator landscape as the realistic context for clinical-translation expectations. The combination of oxiracetam with a choline source (alpha-GPC or CDP-choline) is the most commonly employed nootropic stack and is pharmacologically well rationalized.

13. References

1. Bottini G, Vallar G, Cappa S, et al. Oxiracetam in dementia: a double-blind, placebo-controlled study. *Acta Neurol Scand.* 1992;86(3):237-241.
2. Itil TM, Menon GN, Songar A, Itil KZ. The effects of oxiracetam (ISF 2522) in patients with organic brain syndrome (a double-blind controlled study with piracetam). *Drug Dev Res.* 1982;2(5):447-461.
3. Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. *Drugs.* 2010;70(3):287-312.
4. Li W, Xue J, Niu C, et al. (S)-Oxiracetam is the active ingredient in oxiracetam that alleviates the cognitive impairment induced by chronic cerebral hypoperfusion in rats. *Sci Rep.* 2017;7(1):10052.
5. Chemical synthesis routes. ChemicalBook synthesis database. Oxiracetam (CAS 62613-82-5).
6. O'Neill MJ, Bhatt D. AMPA receptor potentiators for the treatment of CNS disorders. *Curr Drug Targets CNS Neurol Disord.* 2004;3(3):181-194.
7. Spignoli G, Pepeu G. Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. *Pharmacol Biochem Behav.* 1987;27(3):491-495.
8. Fordyce DE, Clark VJ, Paylor R, Bhatt D. Enhancement of hippocampally-mediated learning and protein kinase C activity by oxiracetam in learning-impaired DBA/2 mice. *Brain Res.* 1995;672(1-2):170-176.
9. Villardita C, Grioli S, Lomeo C, Cattaneo C, Parini J. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree. *Neuropsychobiology.* 1992;25(1):24-28.
10. Maina G, Fiori L, Torta R, et al. Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. *Neuropsychobiology.* 1989;21(3):141-145.
11. Green RC, Goldstein FC, Auchus AP, et al. Treatment trial of oxiracetam in Alzheimer's disease. *Arch Neurol.* 1992;49(11):1135-1136.

12. Lu J, Xu L, Chen Y, et al. Efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury: a multicentre, randomised, double-blind, phase 3 clinical trial. *Signal Transduct Target Ther*. 2025;10:196.
13. Lim JS, Rha JH, Park JH, et al. Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: a multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial. *Contemp Clin Trials*. 2023;126:107108.
14. Perucca E, Albrici A, Gatti G, Spalluto P, Visconti M, Crema A. Absorption and disposition of ¹⁴C-labelled oxiracetam in rat, dog and man. *Eur J Drug Metab Pharmacokinet*. 1992;17(4):301-312.
15. Perucca E, Parini J, Albrici A, Visconti M, Ferrero E. Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly. *Eur J Drug Metab Pharmacokinet*. 1987;12(2):145-148.
16. Moglia A, Sinforiani E, Zandrini C, Gualtieri S, Corsico R, Arrigo A. Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study. *Clin Neuropharmacol*. 1986;9(Suppl 3):S73-S78.
17. Spignoli G, Pepeu G. Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. *Pharmacol Biochem Behav*. 1987;27(3):491-495.
18. Giovannini MG, Rodino P, Mutolo V, Pepeu G. Oxiracetam and aniracetam increase acetylcholine release from the rat hippocampus in vivo. *Drug Dev Res*. 1993;28(4):503-509.
19. Bhargava V, Bhargava M. Oxiracetam increases the release of endogenous glutamate from depolarized rat hippocampal slices. *Pharmacol Res*. 1990;22(Suppl 1):94-95.
20. Zhang M, Li H, Liu H, et al. Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: a randomized, double-blind, controlled phase I study. *Eur J Pharmacol*. 2023;960:176132.
21. Zhu X, Wang Y, Chen L, et al. Oxiracetam improves cognitive disorder in AD by modulating AMPAR subunits GluA1/GluA2 kinetics. *Cell Biochem Biophys*. 2026;84:published online.

22. Banfi S, Cornelli U, Fonio W, Dorigotti L. A screening method for substances potentially active on learning and memory. *J Pharmacol Methods*. 1984;11(3):169-174.
23. Pittaluga A, Bhargava V, Bhargava M, Bhargava K. Oxiracetam prevents the hippocampal cholinergic hypofunction induced by the NMDA receptor blocker AP7. *Neurosci Lett*. 1992;143(1-2):127-130.
24. Galli P, Morselli PL, Mandelli V. Biochemical and pharmacological evidence for nootropic activity of oxiracetam. *Pharmacol Res Commun*. 1988;20(Suppl 4):7-14.
25. Zhang H, Jia L, Jia J. Oxiracetam offers neuroprotection by reducing amyloid beta-induced microglial activation and inflammation in Alzheimer's disease. *Front Neurol*. 2020;11:623.
26. Li J, Zhang Y, Gao Y, et al. Oxiracetam ameliorates cognitive deficits in vascular dementia rats by regulating the expression of neuronal apoptosis/autophagy-related genes associated with the activation of the Akt/mTOR signaling pathway. *Braz J Med Biol Res*. 2019;52(11):e8371.
27. Sallustio F, Porcelli P, Pagliarulo A. Pharmacokinetics of oxiracetam in patients with renal impairment after a 800 mg single oral dose. *Eur J Clin Pharmacol*. 1990;39(5):521-523.
28. Copani A, Genazzani AA, Aleppo G, et al. Effect of the nootropic drug oxiracetam on field potentials of rat hippocampal slices. *Br J Pharmacol*. 1992;106(3):563-567.
29. Preda L, Alberoni M, Bressi S, et al. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia. *J Neural Transm (P-D Sect)*. 1988;1(1-2):42-43.
30. Dysken MW, Fovall P, Harris CM, et al. Neuropsychological results of long-term therapy with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia in comparison with a control group. *Neuropsychobiology*. 1989;22(2):72-78.
31. Lim JS, Rha JH, Park JH, et al. Oxiracetam and physical activity in preventing cognitive decline after stroke: a multicenter, randomized controlled trial. *Eur Stroke J*. 2025;published online.

32. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review. *Methods Find Exp Clin Pharmacol*. 2006;28(Suppl B):1-56.
33. Wang Y, Zhang L, Chen S, et al. Comparative toxicity and toxicokinetic studies of oxiracetam and (S)-oxiracetam in dogs. *Regul Toxicol Pharmacol*. 2018;110:189-196.
34. Nakamura K, Tanaka Y. Antianxiety action of aniracetam in three models of anxiety in mice. *Eur J Pharmacol*. 2001;420(1):33-37.
35. Poschel BP, Marriott JG, Stolk JM. Pharmacology of the cognition activator pramiracetam (CI-879). *Drugs Exp Clin Res*. 1985;11(6):393-400.
36. Zvejniece L, Svalbe B, Veinberg G, et al. Investigation into stereoselective pharmacological activity of phenotropil. *Basic Clin Pharmacol Toxicol*. 2011;109(5):407-412.
37. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. *Clin Ther*. 2003;25(1):178-193.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Oxiracetam is not approved by the United States Food and Drug Administration. The compound is registered as a medicine in Italy, select European countries, Argentina, and China; investigators should consult their local regulatory authority before any human research application.